Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients
Open Access
- 6 January 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (15) , 12164-12173
Abstract
Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patientsKeywords
This publication has 32 references indexed in Scilit:
- Cancer classification using the Immunoscore: a worldwide task forceJournal of Translational Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal AdenocarcinomaClinical Cancer Research, 2010
- Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)Annals of Oncology, 2009
- Epstein‐Barr virus associated gastric carcinoma: Epidemiological and clinicopathological featuresCancer Science, 2008
- Epstein-Barr Virus-Positive Gastric Carcinoma Has a Distinct Protein Expression Profile in Comparison with Epstein-Barr Virus-Negative CarcinomaClinical Cancer Research, 2004
- Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric CancerJournal of Clinical Oncology, 2004
- Clinicopathologic Characteristics of Epstein-Barr Virus-Incorporated Gastric Cancers in KoreaPathology - Research and Practice, 2001
- Histology of the Gastroesophageal JunctionAmerican Journal of Surgical Pathology, 2000